Clinical Trials Sponsored by Experien Group

Total 7356 results

Vektor Medical
Experien Group

Completed

Vektor vMap™ Clinical Validation Study

Atrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrythmia | Cardiac Arrhythmia | Premature Ventricular Complexes Multiple | Premature Atrial Complex | Atrioventricular Reentrant Tachycardia

United States
Esperion Therapeutics, Inc.

Completed

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Diabetes Mellitus, Type 2 | Diabetes | Cholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

Hypercholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

Mild Dyslipidemia

United States
Esperion Therapeutics, Inc.

Recruiting

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

Healthy Lactating Women

United States
Esperion Therapeutics, Inc.

Completed

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Hypercholesterolemia | Atherosclerotic Cardiovascular Diseases

United States, United Kingdom, Germany, Poland, Netherlands, Canada
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Atherosclerosis | Hypercholesterolemia | Statin Adverse Reaction

United States
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Hypercholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Type 2 Diabetes | Hyperlipidemia

United States
Esperion Therapeutics, Inc.

Completed

A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects

Safety Evaluation of Escalating Doses

United States
Esperion Therapeutics, Inc.

Recruiting

A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Hypercholesterolemia

United States, Spain, Denmark, Canada, Netherlands, Germany
Esperion Therapeutics, Inc.

Recruiting

Bempedoic Acid Pregnancy Surveillance Program

Pregnancy | Hyperlipidemias

United States
Esperion Therapeutics, Inc.

Completed

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

Hypercholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Dyslipidemia

United States
Esperion Therapeutics, Inc.

Completed

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

United States
MedSIR
AstraZeneca; Experior

Completed

Preoperative Olaparib Endometrial Carcinoma Study (POLEN) (Polen)

Endometrial Carcinoma

Spain
Esperion Therapeutics, Inc.

Completed

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk (CLEAR Wisdom)

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

United States
Esperion Therapeutics, Inc.

Completed

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Hyperlipidemias

United States
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Hypercholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant (CLEAR Serenity)

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Statin Adverse Reaction

United States, Canada
Esperion Therapeutics, Inc.

Completed

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Hyperlipidemia

United States
Esperion Therapeutics, Inc.

Completed

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

Hyperlipidemia

United Kingdom
Augmented eXperience E-health Laboratory

Recruiting

ImGTS for Patients With Cerebral Palsy and With Mobility Limitations (Phase 2)

Cerebral Palsy

Philippines
Augmented eXperience E-health Laboratory

Recruiting

ImGTS for Patients With Behavioral and Psychological Symptoms of Dementia (Phase 2)

Dementia Alzheimers

Philippines
Augmented eXperience E-health Laboratory

Active, not recruiting

ImGTS for Patients With Behavioral and Psychological Symptoms of Dementia

Dementia Alzheimers

Philippines
Esperion Therapeutics, Inc.
Medpace, Inc.

Completed

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Hypercholesterolemia

United States
Experiad LLC
northwest behavioral associates

Unknown

Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1

Autism Spectrum Disorder

United States
Kaiser Permanente
Esperion Therapeutics, Inc.

Not yet recruiting

Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

Cardiovascular Diseases | STEMI | NSTEMI

United States
Esperion Therapeutics, Inc.
Medpace, Inc.

Completed

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Hypertension | Hypercholesterolemia

United States
MedSIR
Roche Pharma AG; Experior

Completed

T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (THELMA)

Breast Cancer

France, Spain
Esperion Therapeutics, Inc.
Medpace, Inc.

Completed

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Hypercholesterolemia

United States
Esperion Therapeutics, Inc.
The Cleveland Clinic

Completed

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)

Cardiovascular Diseases | Statin Adverse Reaction

Belgium, Germany, United States, Austria, Estonia, Mexico, New Zealand, Spain, Russian Federation, Netherlands, Hungary, Australia, Denmark, South Africa, United Kingdom, Bulgaria, Argentina, Romania, Turkey, Croatia, Serbia, Canada, Lithuan... and more
Augmented eXperience E-health Laboratory

Active, not recruiting

ImGTS for Patients With Cerebral Palsy and With Mobility Limitations

Cerebral Palsy

Philippines
Brigham and Women's Hospital
Esperion Therapeutics, Inc.

Recruiting

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy (PAD-ALERT)

Peripheral Vascular Diseases | Dyslipidemias | Peripheral Artery Disease

United States
Utah State University
Utah Agriculture Experiment Station

Completed

The Effect of a Nutrient Dense Food on the Skin CarotenoidLevels of School Age Children

Children, Only | Raman Spectroscopy

United States
Grupo Espanol de Tumores Neuroendocrinos
Eisai Limited; Experior S.L.

Completed

Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors (TALENT)

Neuroendocrine Tumors

Spain, Italy, Austria, United Kingdom
Pfizer
Analysis Group; IMDC group

Completed

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Metastatic Renal Cell Carcinoma (mRCC)

Canada
University of New Hampshire
New Hampshire Agricultural Experiment Station

Recruiting

Fiber-rich Foods, Weight Status, and the Gut Microbiota in NH Hispanic Adults at Risk for Food Insecurity (FIRST)

Food Insecurity | Overweight and Obesity

United States
AGO Study Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Recruiting

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Germany
German Breast Group
AGO Study Group

Completed

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

Breast Cancer

Germany
Groupe Hospitalier Diaconesses Croix Saint-Simon
GERCOR - Multidisciplinary Oncology Cooperative Group

Recruiting

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer (CHIMOVIP)

Ovarian Cancer, Epithelial

France
German Breast Group
AGO Study Group

Completed

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Breast Cancer

Germany
Tera Group

Recruiting

Validation of TERA Bio Station T101 of COVID-19 Tested Population.

COVID-19

Turkey
Polaris Group

Recruiting

ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme (GBM)

Taiwan
RECORDATI GROUP

Recruiting

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease

Cushing's Disease

Italy, Belgium, Bulgaria, Slovenia, United Kingdom
RECORDATI GROUP

Completed

Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome (LINC7)

Cushing's Syndrome

France
RECORDATI GROUP

Completed

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Cushings Disease

Canada, France, Germany, Italy, United States, Israel, Romania, Colombia, Lebanon, Netherlands, United Kingdom
Menarini Group

Active, not recruiting

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01)

Metastatic Colorectal Cancer

Spain, Italy, Netherlands, Germany, United States, France, Poland
Menarini Group

Completed

Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance

Colic

United States
SVR Group

Withdrawn

Evaluation of the Efficacy of Topialyse Baume barrière on Atopic Dermatis (TOPIA)

Atopic Dermatitis

Clinical Trials Sponsored by Experien Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations